A wealth of new and advancing technologies are changing the way we approach research in healthcare. The use of big data sets, precision medicine and machine learning mean that research studies can be bigger, cheaper and wider reaching than ever before. In this lecture, Professor Martin Landray, Deputy Director of the Big Data Institute, and Professor of Medicine and Epidemiology at the University of Oxford, will consider how recent advancements in healthcare technologies have radically changed how we go about medical research, and look at how future innovations could further shape the field.
Martin Landray is Professor of Medicine and Epidemiology within the Nuffield Department of Population Health and Deputy Director of the Big Data Institute within the Li Ka Shing Centre for Health Information and Discovery.
His work seeks to further understanding of the determinants of common life-threatening and disabling diseases through the design, conduct and analysis of efficient, large-scale epidemiological studies (including clinical trials) and the widespread dissemination of both the results and the scientific methods used to generate them. He leads international trials that have enrolled over 65,000 individuals with cardiovascular or kidney disease from 18 countries across 4 continents, and the results of completed studies have changed regulatory drug approvals, influenced clinical guidelines and changed prescribing practice to the benefit of patients. He also oversees the development of systems for recruitment, data collection (including integrated measurement devices and record linkage), analysis and data sharing for UK Biobank, a prospective cohort study of 500,000 middle-aged men and women.
In addition to leading his own research, he is heavily involved in efforts to streamline clinical trials, working with national and international organizations (including FDA, EMA, MHRA, MRC) to facilitate high quality research is efficient in providing robust information for healthcare decision-making. He is a member of the Steering Committee of the Clinical Trial Transformation Initiative (a FDA initiative, coordinated by Duke University) and a leader of the CTTI Monitoring and Quality by Design Projects. He was previously an advisor to the FDA’s initiative to develop standardized definitions for cardiovascular endpoints in clinical trials, a member of the NIHR Commissioning Board, and a member of a UK Department of Health / MRC / MHRA project to promote risk-based monitoring of clinical trials.
Martin Landray completed medical training at University of Birmingham (UK) and specialist training in Clinical Pharmacology & Therapeutics, and General Internal Medicine at University of Birmingham. He continues to practise clinical medicine as an Honorary Consultant Physician in the Cardiology, Cardiac and Thoracic Surgery Directorate at Oxford University Hospitals NHS Trust. He is a Fellow of the Royal College of Physicians of London, the Higher Education Academy, the American Society of Nephrology, and the British Pharmacological Society.